Factors predicting clinical endpoints in Hepatitis Delta: A retrospective-prospective single center study

Introduction: Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alpha is effective in only 25–30% of patients. Thus, it is crucial for the clinical management to distinguish patients who need treatment and individuals with more benign course of liver disease in whom the side-effect-prone and costly antiviral therapy might be delayed. We recently introduced a baseline-event-anticipation (BEA) score for hepatitis delta considering thrombocytes, bilirubin, INR, age, sex and country of origin as factors being associated with the development of clinical endpoints. The aim of this study…